Enhanced ROCK activity has furthermore been observed in PBMCs from SLE patients [32] and the recent development of both panROCK inhibitors and selective ROCK2 inhibitors [33] has opened the possibility that targeting the ROCK-IRF4 axis may represent a novel therapeutic approach for SLE. The gene discussed is ROCK2; the disease is systemic lupus erythematosus.